27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- GlaxoSmithKline Plc (NYSE:GSK), in its Q3 earnings release, revealed that it is stopping the development of otilimab in COVID-19 in patients who are at least 70 years old.
- The Company decided because their already-approved monoclonal antibody Xevudy “plays an important role as a treatment for mild-to-moderate COVID-19 in high-risk adult and pediatric patients,” according to a company statement.
- In February, GSK revealed that a single dose of otilimab failed to improve the likelihood of being alive and free of respiratory failure 28 days later in patients with severe COVID-19-related pulmonary disease.
- While GSK is stopping work on COVID-19, it is continuing to study otilimab in rheumatoid arthritis.
- A phase 3 clinical trial in the indication is scheduled to deliver data in 2H of 2022.
- Xevudy (sotrovimab) is the anti-SARS-CoV-2 antibody GSK is developing with Vir Biotechnology Inc (NASDAQ:VIR).
- Related: Vir Biotech Stock Jumps After FDA Emergency Use Approval COVID-19 Antibody Drug.
- Price Action: GSK shares are up 0.39% at $40.34 during the market session on the last check Wednesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!